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Invasive meningococcal disease (IMD) is a severe disease caused 
by various Neisseria meningitidis serogroups that represents a 
serious public health problem worldwide. In Italy, serogroups B 
and C are the major causes of IMD. On 14 January 2013, the 
European Medicines Agency authorized the use of the first vac-
cine available to protect against meningococcal serogroup B 
(4CMenB).
The aim of this study was to assess the IMD epidemiology 
knowledge and 4CMenB vaccine attitudes of healthcare work-
ers (HCWs) with regard to recommending this vaccine for use, 
vaccine practices and infectious disease control in the Campania 
region in Italy. A cross-sectional study was conducted among 293 
HCWs (49.5% physicians and 46.4% nurses)interviewed using a 
self-administered questionnaire. 
The majority of the HCWs had sufficient knowledge about the dis-
ease incidence and lethality, but they were less informed about 
the higher risk age categories and the serogroups most frequently 
involved. Additionally, their knowledge about the vaccine was 
poor with regard to the targeted categories and side effects. 
Approximately30.0% of the HCWs reported incidences of fever 
and pain and swelling at the injection site. Moreover,32.8% of 
the HCWs knew that the risk of developing adverse reactions 
increases when the 4CMenB vaccine is co-administered with 
other vaccines.
Overall, all of the HCWs were convinced that vaccinations are an 
important instrument for preventing infectious diseases, and they 
were aware of their central role in promoting the 4CmenB vac-
cination and their need to be better informed.
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Introduction
An invasive meningococcal disease (IMD)is a severe 
and a life-threatening disease caused by various Neis-
seria meningitidis serogroups, and it represents a serious 
public health problem worldwide, with an annual num-
ber of cases estimated to be at least 1.2 million [1-3]. In 
Europe, the USA and other industrialized regions, sero-
groups B and C are the major causes of IMDs [4, 5]. Ap-
proximately one in ten cases are fatal, and among those 
who survive, long-term sequelae, such as hearing loss, 
neurological defects or amputation, can occur [6,  7]. 
Vaccination practices (MenC and ACWY135 vaccines) 
have significantly changed the epidemiology of this 
disease, so that serogroup B is currently the predomi-
nant cause of IMDs in Europe, Latin America and North 
America [5, 8, 9]. In Italy, the IMD incidence is higher 
in children 0 to 4 years old than in the other age catego-
ries, particularly in infants less than 1 year old (IMD in-
cidence = 4.01/100,000 in 2013) [10, 11]. The serogroup 
mainly involved in infants less than 1 year old is type B 
(IMD incidence = 3.44/100,000 in 2013), with the high-
est incidence among children younger than 24 months, 
peaking at 4-8 months [10, 12]. Between 2014 and 2016, 
the IMD incidence among individuals 15-24 years old 
increased, from 0.30/100,000 in 2014 to 0.90/100,000 in 
2016, and decreased in adults older than 25 years during 
the same time period [10]. 
In Italy, the IMD surveillance system based on labo-
ratory-confirmed cases (almost 70%) revealed that be-
tween 2011 and 2017, serogroup B was the most com-
mon IMD-causing type [10], except between 2015 and 
2016 when a hyper virulent meningococcal C strain was 
responsible for an unexpected increased IMD incidence 
in the Tuscany region. Following this episode, the Ital-
ian Health Authorities implemented immunization cam-
paigns and enhanced IMD surveillance. On 14 Janu-
ary 2013, the European Medicines Agency authorized 
the use of the first vaccine available to protect against 
meningococcal serogroup B (Bexsero; GSK, Philadel-
phia, PA, USA) [13-16]. It is a multicomponent vaccine 
(4CMenB) composed of three purified recombinant an-
tigenic proteins from Neisseria meningitides serogroup 
B and the outer membrane vesicles of the bacterium. 
The 4CMenB vaccination schedule for infants consists 
of three doses: the first dose is given at three months 
old, the second dose is given between 1 and 2 months 
after the first dose, and the third “booster” dose is given 
at 13 months old. As with other vaccinations, the most 
common adverse reactions from the4CMenB vaccina-
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tion consist of fever, pain and swelling at the injection 
site, abnormal crying and irritability, eating disorders 
and gastrointestinal symptoms, sleepiness and a cutane-
ous rash. The uncommon adverse reactions consist of 
febrile or non-febrile convulsions and pallor, while the 
rarest adverse reactions are urticaria and Kawasaki syn-
drome [17].
The 4CMenB vaccination strategy differs across the Eu-
ropean countries; for example, in Italy, the vaccination 
strategies are set out by different regions through the Re-
gional Health Plan. This plan must respect the guidelines 
defined by the National Health Plan and the National 
Vaccine Prevention Plan (Piano Nazionale Prevenzione 
Vaccinale, PNPV) [18]. The latter defines the best vacci-
nation policy to be carried out in each region in accord-
ance with the best scientific evidence available. Each re-
gion can issue their own vaccination strategy in terms of 
the target population and costs that might being incurred 
by the citizens. This can lead to differences in the vac-
cine administration across Italian regions, resulting in 
heterogeneous vaccine coverage. The decreasing immu-
nization adherence trend in Italy over recent years fur-
ther compromises homogeneous and efficacious vaccine 
coverage, and this includes an unjustified fear of adverse 
reactions, scarce awareness regarding severe outcomes 
when not vaccinated, and the media’s role in spreading 
incorrect information about vaccines. Many people’s at-
titudes toward vaccinations may have been affected after 
an unverified association between the measles, mumps 
and rubella vaccine and autism was reported by the me-
dia, as well as after the Fluad case. The latter followed 
the withdrawal of the Novartis vaccine against influenza 
by the Italian Medicines Agency known as “Agenzia 
Italiana del Farmaco” after the occurrence of 3 deaths in 
48 hours. Although there was prompt readmission of the 
Novartis vaccine, the media event had already affected 
people’s attitudes towards vaccinations. These events 
have increased both citizens and healthcare workers’ 
(HCWs) loss of faith in Italian institutions.
Previous studies have documented the strong influence 
that HCWs have on a patient’s decision making process 
regarding whether or not to undergo vaccination [19-22]. 
However, some HCWs feel poorly informed and poorly 
trained on how to answer patient questions, and they of-
ten struggle when dealing with those who distrust the 
efficacy and safety of vaccines [23, 24]. Therefore, the 
aim of our study was to assess the knowledge and at-
titudes of HCWs involved in vaccination programs and 
infectious disease control with regard to recommending 
the 4CMenB vaccine in the Campania region of Italy.
Methods
Participants and setting
Within each Local Health Service (Aziende Sanitarie 
Locali, ASL) that manages public healthcare, the com-
municable disease prevention is run by two departments, 
the Maternal Childhood Health Protection Department, 
which delivers vaccines to children through its Mater-
nal Childhood Operative Unit (Unità Operativa Materno 
Infantile, UOMI), and the Public Health Department, 
which looks at infectious disease surveillance and con-
trol through the Epidemiology Service (Servizio di Epi-
demiologia e Prevenzione) and Public Hygiene Service 
(Servizio di Igiene e Sanità Pubblica) and administers 
vaccines to adults and travellers through the Collective 
Prevention Operative Unit (Unità Operativa Prevenzione 
Collettiva).
A cross-sectional study was conducted from 1 January 
2017 through 30 June 2017 at the ASLs in the metro-
politan areas of Naples, Caserta and Salerno in the Cam-
pania region among the HCWs involved in the surveil-
lance and control of infectious diseases or vaccine ad-
ministration (the total number of HCWs at these ASLs 
was around 750). In each unit, a healthcare operator was 
identified as a reference contact, and they collaborated to 
explain the study objectives and raise awareness among 
the HCWs. In addition, this individual distributed the 
questionnaires and collected them immediately after 
they were completed anonymously by the participants. 
The questionnaires focused on the HCWs’ knowledge 
about IMD epidemiology and preventability and their at-
titudes towards 4CMenB vaccine use. It consisted of 45 
items gathered into 3 main topics described as follows:
1. Socio-demographic information (sex, age, marital 
status, how many children, any children < 5 years 
old, education, degree type and medical specialty) 
and professional characteristics (ASL, workplace, 
occupational category, type of activity and seniority).
2. Knowledge about serogroup B meningococcal dis-
ease and the 4CMenB vaccine (epidemiology of 
meningococcal meningitis in Italy and its lethality 
and mortality rate, knowledge about the 4CMenB 
vaccination and its side effects).
3. Attitudes toward vaccination practices, specifically 
toward the 4CMenB vaccination (opinions about the 
4CMenB vaccine, its efficacy and safety, the oppor-
tunity to recommend it and make it mandatory; opin-
ions about the reasons why parents do or do not vac-
cinate their children), and updating resources (self-
evaluation of their own level of knowledge about the 
4CMenB vaccine and updating resources used).
Sample size
The number of HCWs needed was determined on the as-
sumption that 75% of the HCWs had appropriate knowl-
edge regarding IMDs and the 4CmenB vaccine, a con-
fidence interval of 95% and a ratio unexp/exp 1:2. The 
results showed that a total number of 365 HCWs needed 
to be enrolled in the study. 
Data analysis
The data was analysed using Stata: Data Analysis and 
Statistical Software version 10.1 (Stata Corp LLC, Col-
lege Station, TX, USA). Following the descriptive anal-
ysis, a univariate analysis was performed using a chi-
squared test to identify the associations between each 
independent variable and the outcomes of interest. Then, 
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only those variables with a p value < 0.25 in the uni-
variate analysis were included in the final multivariate 
logistic regression models. The p values were assessed 
using two-sided tests, with the statistical significance for 
p defined at a value of ≤ 0.05. 
The independent variables were the sex, age, number of 
children, education, occupational category, department 
type and activity type. The dependent variables were the 
knowledge about meningococcal meningitis (incidence, 
most common serogroup in Italy, lethality and mortality 
rate) and knowledge about the 4CMenB vaccine (vac-
cine recommended age groups, vaccinations schedule, 
inclusion or exclusion among recommended vaccina-
tions by the PNPV in Italy and by the Regional Vaccine 
Prevention Plan in Campania, and risk for adverse reac-
tions when the 4CMenB vaccine is co-administered with 
another vaccine).
Ethical considerations 
All of the participants were informed that the data was 
collected anonymously and stored in a confidential man-
ner. None of the participants could be identified based 
on the material submitted, and no incentives were of-
fered to the HCWs for their participation in this study.
Results
A total of 293 HCWs completed the survey, with a re-
sponse rate of 80.3%. As shown in Table I, 63.8% were 
women, 65.9% were between 41 and 59 years old, 79.2% 
were married, 83.6% had at least one child, 6.1% had a 
child less than 5 years old, 55.6% had graduated, and 
7.4% and 88.9% had graduated from nursing and medi-
cine, respectively. Among those who were physicians, 
the majority were specialists in hygiene and preventive 
medicine (35.2%), 21.4% were in paediatrics and just 
a few of them were specialists in infectious diseases 
(4.8%). Moreover, 50.8% of the HCWs worked in ASLs 
in Naples, 51.9% worked in UOMIs, the majority were 
physicians (49.5%), 46.4% were nurses and only 4.1% 
were other types of HCWs, like medical assistants, bi-
ologists and professional educators. Additionally, 51.9% 
of the participants were directly involved in vaccination 
programs, 17.1% were in infectious disease surveillance 
and control, and 23.2% were involved in both activities.
Table II shows the results of the IMD knowledge among 
the physicians and nurses with relative confidence inter-
vals; 24.1% of the physicians and 17.7% of the nurses 
reported that the meningococcal meningitis incidence in 
Italy was not high, while 50.3% of the physicians and 
only 38.2% of the nurses identified serogroup B as the 
most common. Regarding the age groups at a higher risk 
of contracting meningococcal meningitis, 27.3% of the 
HCWs indicated  < 1 year old, 30.6% indicated from 
1-4 years old and 27.3% indicated from 15-24 years old; 
however, only 7.6% of the physicians and 4.4% of the 
nurses indicated all three age groups that were at a high-
er risk (data not shown). Moreover, 80.4% of the HCWs 
indicated that the meningococcal meningitis lethality 
rate was high, while 48.3% and 36.0%,respectively, in-
dicated that the mortality rate was very low.
The results from the HCWs’ knowledge about the 
4CmenB vaccine are described in Table III. Most of 
the participants (69.0%) had at least sufficient knowl-
edge about the 4CMenB vaccine, and 79.4% had suf-
ficient knowledge about its vaccination schedule. How-
ever, only 34.1% of the HCWs indicated < 1 year old as 
the targeted group for the 4CMenB vaccination, while 
18.2% and 20.5% indicated 1-4 years old and immune-
suppressed individuals, respectively. Only 2.7% of the 
physicians and 2.9% of the nurses correctly identified 
all three targeted groups (results not shown). In order to 
assess their knowledge about the vaccination schedule, 
the HCWs were asked about the number of doses, tim-
ing and whether a booster shot was needed. Only 31.0% 
of the physicians and 21.3% of the nurses knew the 
4CMenB vaccination schedule for all of the age groups.
Tab. I. Sociodemographic and professional characteristics of the 
healthcare workers (HCWs) (n = 293).
n %
Sex 98 33.5 98
187 63.8 187
8 2.7 8
293 100.0 293
Age ≤ 40 8 2.7
41–59 193 65.9
≥ 60 84 28.7
No response 8 2.7
Total 293 100.0
Marital 
status
Married 232 79.2
Unmarried 23 7.9
Widow/Widower 4 1.4
Separate/Divorced 11 3.7
No response 23 7.8
Total 293 100.0
Have 
children
Yes 245 83.6
No 32 10.9
No response 16 5.5
Total 293 100.0
Children 
less than 5 
years old a
Yes 15 6.1
No 230 93.9
Total 245 100.0
Type of 
degree b
Medicine 145 88.9
Nursing 12 7.4
Other 6 3.7
Total 163 100.0
Medical 
specialty c
Hygiene and 
preventive 
medicine
51 35.2
Paediatrics 31 21.4
Infectious disease 7 4.8
Other 17 11.7
Not specialized 39 26.9
Total 145 100.0
UOPC: Collective Prevention Operative Unit; UOMI: Maternal Childhood 
Operative Unit; SEP: Epidemiology Service ; SISP :Public Hygiene Service ; a 
Calculated only for the HCWs who reported at least one child (n = 245); b 
Calculated only for the HCWs who graduated (n = 163); c Calculated only 
for the physicians (n = 145).
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Of the HCWs, 62.6% knew that the PNPV recommends 
the 4CMenB vaccine, while only 30.6% knew that the 
Regional Campania Vaccine Prevention Plan has not im-
plemented the 4CMenB vaccine. 
When assessed with regard to the 4CMenB-related ad-
verse reactions (Tab. IV), 32.0% of the HCWs reported 
fever and 31.0% reported pain and swelling at the injec-
tion site. A few of the HCWs identified gastrointestinal 
disorders, headaches, somnolence, asthenia, convulsions, 
pallor, Kawasaki syndrome, malaise and arthralgia among 
the possible adverse reactions to the vaccine (data not 
shown). Only 32.8% of the HCWs knew that the risk of 
developing adverse reactions increases when the 4CMenB 
vaccine is co-administered with other vaccines. In addi-
tion, 40.0% of the physicians and 52.2% of the nurses 
knew that the 4CMenB vaccine must be administered sev-
eral days after the other recommended vaccinations, while 
36.2% of the physicians and only 15.5% of the nurses 
knew that the main reason for this was the increased risk 
for adverse reactions. Most of the physicians (81.4%) and 
nurses (72.8%) disagreed with the idea that the inclusion 
of the 4CMenB vaccine in the vaccination schedule would 
reduce adherence to the other vaccinations. 
As shown in Table V, 56.6% of the HCWs stated that the 
4CMenB vaccine was extremely efficacious, and 65.5% 
stated that the vaccine was safe. Additionally, 90.4% of the 
HCWs stated that encouraging people to allow their chil-
dren to receive the 4CMenB vaccine was their professional 
duty, and 53.4% would make it mandatory. The fear of the 
disease and its complications was the reason most often giv-
en by the HCWs (61.9%) to address why the parents chose 
to vaccinate their children, while the fear of severe adverse 
reactions (31.6%), disinformation (24.0%) and a poor per-
ception of the disease severity (20.5%) were the most com-
mon reasons why the parents chose not to vaccinate their 
children. Almost all of the HCWs(91.5%) believed that the 
Tab. II. Healthcare workers’ (HCWs) knowledge about the meningococcal meningitis epidemiology (n = 281).
Physicians Nurses Total
% (95% CI) % (95% CI) n %
In Italy the incidence 
of meningococcal 
meningitis is high, do 
you agree?
Strongly agree 3.4 (1.3-5.4) 4.4 (2.0-6.7) 11 3.9
Somewhat agree 16.6 (12.3-20.8) 21.3 (16.6-25.9) 53 18.9
Somewhat disagree* 53.8 (48.0-59.5) 45.6 (39.9-51.3) 140 49.8
Disagree* 24.1 (19.2-29.0) 17.7 (13.3-22.0) 59 21.0
Don’t know/
No response 2.1 (0.4-3.7) 11.0 (7.4-14.5) 18 6.4
Total 100.0 100.0 281 100
Which are the 
most common 
meningococcus 
serogroups in Italy?
Serogroup A 0.0 0.0 0 0.0
Serogroup B* 26.2 (21.1-31.2) 19.1 (14.6-23.6) 64 22.8
Serogroup B
and C* 24.1 (19.2-29.0) 19.1 (14.6-23.6) 61 21.7
Serogroup C 47.6 (41.8-53.3) 59.6 (53.9-65.2) 150 53.4
Serogroup Y or 
serogroup W135 0.0 0.7 (-0.2-1.6) 1 0.3
Don’t know/
No response 2.1 (0.46-3.74) 1.5 (0.1-2.8) 5 1.8
Total 100.0 100.0 281 100.0
Which are the age 
categories at higher 
risk in Italy? 
(more than one 
answer allowed)a
< 1 year* 29.2 (23.9-34.4) 25.4 (20.4-30.3) 114 27.3
1-4 years* 33.0 (27.6-38.3) 28.2 (23.0-33.3) 128 30.6
5-14 years 10.5 (6.9-14.0) 8.1 (4.9-11.2) 39 9.3
15-24 years* 22.0 (17.2-26.7) 32.6 (27.2-37.9) 114 27.3
> 25 years 4.3 (1.9-6.6) 4.3 (1.9-6.6) 18 4.3
Don’t know/
No response 1.0 (-0.1-2.1) 1.4 (0.0-2.7) 5 1.2
Total 100.0 100.0 418 100.0
Is meningococcal 
type B meningitis a 
lethal disease?
Yes* 82.1 (77.7-86.4) 78.7 (74.0-83.3) 226 80.4
No 10.3 (6.8-13.7) 12.5 (8.7-16.2) 32 11.4
Don’t know/
No response 7.6 (4.5-10.6) 8.8 (5.5-12.0) 23 8.2
Total 100.0 100.0 281 100.0
How high is the 
meningococcal 
type B meningitis 
mortality rate in 
Italy? 
Very high 2.1 (0.4-3.7) 5.1 (2.5-7.6) 10 3.6
High 30.3 (25.0-35.5) 28.0 (22.8-33.1) 82 29.2
Low* 11.0 (7.4-14.5) 14.7 (10.6-18.7) 36 12.8
Very low* 48.3 (42.5-54.0) 36.0 (30.5-41.5) 119 42.3
Don’t know/
No response 8.3 (5.1-11.4) 16.2 (11.9-20.4) 34 12.1
Total 100.0 100.0 281 100.0
CI: confidence interval; *Correct answer; a Calculated based on the total number of answers given by the HCWs (n = 418).
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distrust that the parents had with regard to vaccinating their 
children had no scientific basis.
Of the participants, 98.9% stated that HCWs must con-
stantly be updated on vaccination-related scientific evi-
dence, and 85.8% stated that they needed better informa-
tion. In addition, the HCWs reported courses and confer-
ences (30.5%) and the internet (26.2%) as their major 
sources of information about the 4CMenB vaccine. 
Table VI shows the results of the multivariate models 
for which significant associations were identified be-
tween the variables and the outcomes of interest. The 
knowledge about the most common serogroup was 
lower among those HCWs who were < 50 years old 
[odds ratio (OR) = 2.02, 95% confidence interval (CI) = 
1.1-3.6, p = 0.022)]. Moreover, the HCWs who worked 
in the Public Health Department and those who were 
Tab. III. Knowledge about the meningococcal serogroup B multicomponent (4CMenB) vaccine (n = 281).
Physicians Nurses Total
% (95% CI) % (95% CI) n %
What do you 
consider your overall 
knowledge about 
the 4CMenB vaccine 
to be?
Scarce 8.3 (5.1–11.4) 14.7 (10.6–18.7) 32 11.4
Not sufficient 19.3 (14.7–23.8) 19.9 (15.3–24.4) 55 19.6
Sufficient 36.6 (31.0–42.1) 30.1 (24.8–35.3) 94 33.5
Good 30.3 (25.0–35.5) 35.3 (29.8–40.7) 92 32.7
Excellent 5.5 (2.8–8.1) 0.0 8 2.8
Total 100.0 100.0 281 100.0
Are you familiar 
with the4CMenB 
vaccination 
schedule?
Yes 82.0 (77.6–86.4) 76.5 (71.6–81.3) 223 79.4
No 18.0 (13.6–22.4) 23.5 (18.6–28.3) 58 20.6
Total 100.0 100.0 281 100.0
Which age groups 
are recommended to 
receive the 4CMenB 
vaccination? (more 
than one answer 
allowed)a
< 1 year* 34.9 (29.4–40.3) 33.2 (27.8–38.5) 199 34.1
1-4 years* 20.5 (15.8–25.1) 15.5 (11.3–19.6) 106 18.2
5-14 years 8.1 (4.9–11.2) 6.1 (3.3–8.8) 42 7.2
15-24 years 14.7 (10.6–18.7) 16.3 (12.0–20.5) 90 15.4
> 25 years 1.3 (0.0–2.6) 3.6 (1.4–5.7) 14 2.4
Immunosuppressed* 19.5 (14.9–24.0) 21.7 (16.9–26.4) 120 20.5
Don’t know/No 
response 1.0 (-0.1–2.1) 3.6 (1.4–5.7) 13 2.2
Total 100.0 100.0 584 100.0
Infants
Assessment of the 
HCWs’ knowledge 
about the 4CMenB 
vaccination 
schedule for each 
of the following age 
groups:
Correct 47.6 (41.8–53.3) 36.8 (31.2–42.3) 119 42.3
Incorrect 52.4 (46.6–58.1) 63.2 (57.6–68.7) 162 57.7
Total 100.0 100.0 281 100.0
Children
Correct 42.8 (37.1–48.4) 39.7 (34.1–45.3) 116 41.3
Incorrect 57.2 (51.5–62.8) 60.3 (54.7–65.9) 165 58.7
Total 100.0 100.0 281 100.0
Teenagers
Correct 45.5 (39.8–51.2) 34.6 (29.1–40.0) 113 40.2
Incorrect 54.5 (48.8–60.2) 65.4 (59.9–70.8) 168 59.8
Total 100.0 100.0 281 100.0
All ages
Correct 31.0 (25.7–36.3) 21.3 (16.6–25.9) 74 26.3
Incorrect 69.0 (63.7–74.3) 78.7 (74.0–83.3) 207 73.7
Total 100.0 100.0 281 100.0
Has the 4CMenB 
vaccination been 
included among 
those recommended 
by the National 
Vaccine Prevention 
Plan in Italy?
Yes* 64.2 (58.7–69.6) 61.0 (55.4–66.5) 176 62.6
No 18.6 (14.1–23.0) 22.8 (18.0–27.6) 58 20.7
Don’t know 17.2 (12.8–21.5) 16.2 (11.9–20.4) 47 16.7
Total 100.0 100.0 281 100.0
Has the 4CMenB 
vaccination been 
included in the 
Regional Campania 
Vaccine Prevention 
Plan in Campania?
Yes 40.7 (35.0–46.3) 33.8 (28.3–39.2) 105 37.4
No* 27.6 (22.4–32.7) 33.8 (28.3–39.2) 86 30.6
Don’t know 31.7 (26.3–37.0) 32.4 (27.0–37.7) 90 32.0
Total 100.0 100.0 281 100.0
CI: confidence interval, HCWs: healthcare workers; * Correct answer;  a Calculated based on the total number of answers given by the HCWs (n = 584).
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Tab. IV. Knowledge about the risks related to the meningococcal serogroup B multicomponent (4CMenB) vaccine (n = 281).
Physicians Nurses Total
% (95% CI) % (95% CI) n %
How frequently occurring are the 
following 4CMenB vaccine side effects?
Fever Correct 34.5 (29.0-39.9) 29.4 (24.1-34.6) 90 32.0
Incorrect 65.5 (60.0-70.9) 70.6 (65.3-75.8) 191 68.0
Total 100.0 100.0 281 100.0
Pain and 
swelling at the 
injection site
Correct 32.4 (27.0-37.7) 29.4 (24.1-34.6) 87 31.0
Incorrect 67.6 (62.2-72.9) 70.6 (65.3-75.8) 194 69.0
Total 100.0 100.0 281 100.0
Irritability Correct 26.2 (21.1-31.2) 21.3 (16.6-25.9) 67 23.8
Incorrect 73.8 (68.7-78.8) 78.7 (74.0-83.3) 214 76.2
Total 100.0 100.0 281 100.0
Cutaneous 
rash
Correct 6.9 (4.0-9.8) 8.1 (4.9-11.2) 21 7.5
Incorrect 93.1 (90.2-96.0) 91.9 (88.7-95.0) 260 92.5
Total 100.0 100.0 281 100.0
Does the risk of developing an adverse 
reaction increase when the 4CMenB 
vaccine is co-administered with another 
vaccine?
Yes* 34.5 (29.0-39.9) 30.9 (25.6-36.1) 92 32.8
No 46.2 (40.4-51.9) 48.5 (42.7-54.2) 133 47.3
Don’t know 19.3 (14.7-23.8) 20.6 (15.9-25.2) 56 19.9
Total 100.0 100.0 281 100.0
Must the 4CMenB vaccine be 
administered several days after any 
other vaccination?
Yes* 40.0 (34.3-45.6) 52.2 (46.4-57.9) 129 45.9
No 28.3 (23.1-33.4) 22.8 (18.0-27.6) 72 25.6
It makes no 
difference 20.7 (16.0-25.3) 10.3 (6.8-13.7) 44 15.7
Don’t know 11.0 (7.4-14.5) 14.7 (10.6-18.7) 36 12.8
Total 100.0 100.0 281 100.0
Why must the 4CMenB vaccine be 
administered several days after any 
other vaccination? (more than one 
answer allowed) a
To avoid an 
increased risk 
for adverse 
reactions*
36.2 (30.7-41.7) 15.5 (11.3-19.6) 32 24.8
Vaccination 
schedule is 
too busy
15.5 (11.3-19.6) 22.5 (17.7-27.2) 25 19.4
To better asses 
adverse 
reactions
10.4 (6.9-13.9) 4.3 (1.9-6.6) 9 7.0
To improve 
patient 
compliance
6.9 (4.0-9.8) 5.6 (2.9-8.2) 8 6.9
To avoid 
hyperstimulation 
of immune 
system
6.9 (4.0-9.8) 1.4 (0.0-2.7) 5 3.9
To reduce 
parents’ anxiety 0.0 2.8 (0.9-4.6) 2 1.4
No 
response 24.1 (19.2-29.0) 47.9 (42.1-53.6) 46 35.6
Total 100.0 100.0 129 100.0
In your opinion, would any other 
vaccination be refused if the 4CMenB 
vaccination was added to the 
vaccination schedule?
Yes 2.1 (0.4-3.7) 7.4 (4.4-10.4) 13 4.6
No 81.4 (76.9-85.8) 72.8 (67.7-77.9) 217 77.2
Don’t know 16.5 (12.2-20.7) 19.8 (15.2-24.3) 51 18.2
Total 100.0 100.0 281 100.0
If yes, which of the following 
vaccinations would be refused? (more 
than one answer allowed) b
Trivalent 
vaccine 16.7 (12.4-20.9) 43.8 (38.1-49.4) 8 36.4
Pneumococcus 33.3 (27.9-38.7) 25.0 (20.0-29.9) 6 27.3
Hexavalent 
vaccine 16.7 (12.4-20.9) 25.0 (20.0-29.9) 5 22.7
Meningococcal C 33.3 (27.9-38.7) 6.2 (3.4-8.9) 3 13.6
Total 100.0 100.0 22 100.0
CI: confidence interval; * Correct answer; a Calculated based on the total number of answers given by the healthcare workers (n = 129); b Calculated based 
on the total number of answers given by the healthcare workers who answered yes to the previous question (n = 22).
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Tab. V. Healthcare workers’ (HCWs) attitudes toward the meningococcal serogroup B multicomponent (4CMenB) vaccine use and updating 
sources (n = 281).
Physicians Nurses Total
% (95% CI) % (95% CI) n %
Is the 4CMenB vaccine efficacious in 
preventing bacterial meningitis?
Extremely efficacious 55.9 (50.2-61.5) 57.4 (51.7-63.0) 159 56.6
Efficacious 40.0 (34.3-45.6) 39.7 (34.1-45.3) 112 39.9
Scarcely efficacious 4.1 (1.8-6.3) 2.9 (0.9-4.8) 10 3.5
Inefficacious 0.0 0.0 0 0.0
Total 100.0 100.0 281 100.0
Is the 4CMenB vaccine safe? Extremely safe 28.3 (23.1-33.4) 30.9 (25.6-36.1) 83 29.6
Safe 66.2 (60.7-71.6) 64.7 (59.2-70.1) 184 65.5
Scarcely safe 5.5 (2.8-8.1) 1.5 (0.1-2.8) 10 3.5
Not safe 0.0 2.9 (0.9-4.8) 4 1.4
Total 100.0 100.0 281 100.0
Do you consider encouraging people 
to get the 4CMenB vaccination to be an 
HCWs’ professional duty?
Yes 91.7 (88.5-94.8) 89.0 (85.4-92.5) 254 90.4
No 2.1 (0.4-3.7) 2.9 (0.9-4.8) 7 2.5
Don’t know 6.2 (3.4-8.9) 8.1 (4.9-11.2) 20 7.1
Total 100.0 100.0 281 100.0
Would you agree to make the 4CMenB 
vaccination mandatory?
Yes 56.5 (50.8-62.1) 50.0 (44.2-55.7) 150 53.4
No 26.9 (21.8-31.9) 27.9 (22.7-33.0) 77 27.4
Don’t know 16.6 (12.3-20.8) 22.1 (17.3-26.8) 54 19.2
Total 100.0 100.0 281 100.0
Why do people decide to vaccinate their 
children? (more than one answer allowed)a
Fear of the disease and its 
complications 60.7 (55.1-66.2) 63.3 (57.7-68.8) 245 61.9
Vaccination is mandatory 25.6 (20.6-30.6) 24.9 (19.9-29.8) 100 25.3
Vaccine is safe 10.4 (6.9-13.9) 9.7 (6.3-13.0) 40 10.1
Correct information provided 
by HCWs 1.4 (0.0-2.7) 0.5 (-0.3-1.3) 4 1.0
Trust the source that 
recommends the vaccination 0.5 (-0.3-1.3) 0.5 (-0.3-1.3) 2 0.4
Increased number of new cases 
within the community 0.5 (-0.3-1.3) 0.0 1 0.3
Don’t know 0.9 (-0.1-1.9) 1.1 (0.0-2.2) 4 1.0
Total 100.0 100.0 396 100.0
Why do people decide not to vaccinate 
their children? (more than one answer 
allowed)b
Fear of adverse reactions 31.8 (26.4-37.1) 31.3 (25.9-36.6) 208 31.6
Disinformation 21.3 (16.6-25.9) 26.9 (21.8-31.9) 158 24.0
Poor perception of disease 
severity 22.4 (17.6-27.1) 18.4 (13.9-22.8) 135 20.5
Vaccine is not mandatory 11.1 (7.5-14.7) 10.4 (6.9-13.9) 71 10.8
Fear of unknown long-term 
effects 8.2 (5.0-11.3) 8.9 (5.6-12.1) 56 8.5
Vaccination schedule is too busy 4.0 (1.7-6.2) 3.2 (1.1-5.2) 24 3.6
Costs 0.3 (-0.3-0.9) 0.6 (-0.2-1.4) 3 0.4
Advertisement campaigns on 
websites 0.6 (-0.2-1.4) 0.0 2 0.3
Don’t know 0.3 (-0.3-0.9) 0.3 (-0.3-0.9) 2 0.3
Total 100.0 100.0 659 100.0
Do you consider the parents’ choice not to 
vaccinate their children to be scientifically 
based?
Yes 1.4 (0.0-2.7) 1.5 (0.1-2.8) 4 1.4
No 93.8 (91.0-96.5) 89.0 (85.4-92.5) 257 91.5
Don’t know 4.8 (2.3-7.2) 9.5 (6.1-12.8) 20 7.1
Total 100.0 100.0 281 100.0
Must HCWs be constantly updated on 
vaccination-related scientific evidence?
Yes 99.3 (98.3-100.2) 98.5 (97.1-99.8) 278 98.9
No 0.0 0.0 0 0.0
Don’t know 0.7 (-0.2-1.6) 1.5 (0.1-2.8) 3 1.1
Total 100.0 100.0 281 100.0
Do you need to be better informed about 
the 4CMenB vaccine?
Yes 82.1 (77.7-86.4) 89.7 (86.2-93.1) 241 85.8
No 13.1 (9.2-16.9) 7.3 (4.3-10.2) 29 10.3
Don’t know 4.8 (2.3-7.2) 3.0 (1.0-4.9) 11 3.9
Total 100.0 100.0 281 100.0
continues
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involved in the surveillance and control of the disease 
(OR = 0.29, 95% CI = 0.1–0.5, p = 0.000 and OR = 0.35, 
95% CI  = 0.1-0.8, p = 0.015, respectively) were more 
likely to have this knowledge. Being male and being 
involved in the surveillance and control of the disease 
(OR = 0.51, 95% CI = 0.2-0.9, p = 0.034 and OR = 0.34, 
95% CI = 0.1-0.8, p = 0.014, respectively) were associ-
ated with greater knowledge about the meningococcal B 
meningitides mortality rate.
Working in the Public Health Department (OR = 3.31, 
95% CI = 1.6-6.7, p = 0.001) was the only variable as-
sociated with knowledge about the 4CMenB vaccination 
schedule. Additionally, knowledge about the National 
Health Plan was lower among those who worked in 
the Public Health Department (OR = 3.22, 95% CI = 
1.8-5.5, p = 0.000). Being involved in the surveillance 
and control of the disease(OR = 2.83, 95% CI = 1.2-
6.3, p = 0.012) was associated with lesser knowledge 
about the Regional Health Plan, while this knowledge 
was higher among the HCWs who worked in the Pub-
lic Health Department (OR = 0.36, 95% CI = 0.2-0.6, 
p = 0.001). Not having children and working in the Pub-
lic Health Department (OR = 0.41, 95% CI = 0.1-0.8, 
p = 0.020 and OR = 1.76, 95% CI = 1.0-2.9, p = 0.037, 
respectively) were associated with knowledge about the 
increased risk for adverse reactions when the 4CMenB 
vaccine was co-administered with another vaccine.
Discussion
This study was conducted after the 4CMenB vaccine was 
placed on the market. This vaccine specifically prevents 
serogroup B meningitis, which is the serogroup most 
frequently involved in this disease, and against which 
no traditionally made vaccines were previously availa-
ble. Since its approval for use, many concerns about the 
most appropriate vaccination strategy have been raised 
within the international and national scientific commu-
nities [17]. In fact, in the years following the 4CMenB 
vaccine being placed on the market, the scientists and 
public health advisors in charge of health policies have 
had different opinions on how to provide the 4CMenB 
vaccine to the general population  [14]. Therefore, the 
aim of the present study was to assess HCWs’ knowl-
edge about the 4CMenB vaccine and its vaccination 
strategy, while considering the role HCWs play in im-
plementing vaccination coverage (whatever their posi-
tion) within operative or decision-making units.
The present analysis determined that the majority of 
HCWs have sufficient knowledge about the lethality of 
the disease, but they are less informed about the inci-
dence, higher risk age categories and most frequent sero-
groups involved. Many of them are confused about what 
is meant by mortality and lethality, and they mistak-
enly consider this disease to have a high mortality rate 
in the general population. The majority of the HCWs 
considered their knowledge about the vaccine and its 
vaccination schedule to be good, but only a few iden-
tified all of the targeted categories. This is particularly 
evident when considering immunosuppressed individu-
als, who are considered by the scientific community to 
be the group at highest risk and the most appropriate to 
receive the vaccine; however, they were identified as a 
target category by few of the HCWs. Moreover, some of 
the HCWs’ answers were not consistent. For instance, 
one-third of the nurses believed that administering the 
4CMenB vaccine with another vaccine enhanced the risk 
for adverse reactions, but only 15.0% indicated that the 
4CMenB vaccine must be administered several days af-
ter another vaccine in order to reduce the risk for adverse 
reactions. Interestingly, those HCWs involved in surveil-
lance and control activities had more knowledge about 
the epidemiological characteristics of the disease when 
compared with those working in the UOMI, where the 
HCWs are mainly involved in administering the vaccine 
to children. However, the HCWs working in the UOMI 
had better knowledge about the 4CmenB vaccination 
strategy and adverse reactions.
It was unexpected that only a few of the HCWs knew 
about the PNPV (60.0% of the HCWs) and Campania 
Vaccine Prevention Plan (30.0% of the HCWs) indica-
tions about 4CmenB vaccine use, considering that both 
of these documents represent reference tools for HCWs.
One limitation of this study was that the questionnaire 
was self-administered; therefore, we cannot be sure that 
Tab. V. follows.
How did you get informed about the 
4CMenB vaccine? (more than one answer 
allowed) c
Updating courses/congresses 7.6 (4.5–10.6) 11.4 (7.7–15.0) 46 9.3
Internet 9.7 (6.3–13.0) 5.0 (2.5–7.5) 38 7.7
National journals 1.5 (0.1–2.8) 7.8 (4.7–10.8) 21 4.2
Pharmaceutical promoters 0.7 (-0.2–1.6) 3.2 (1.1–5.2) 9 1.8
International journals 0.0 3.6 (1.4–5.7) 8 1.6
Television 0.4 (-0.3–1.1) 0.5 (-0.3–1.3) 2 0.4
Vaccine information leaflets 2.2 (0.5–3.8) 3.6 (1.4–5.7) 14 2.8
Colleagues 1.1 (0.0–2.2) 1.4 (0.0–2.7) 6 1.2
National health plan 100.0 100.0 496 100.0
No source of updating 7.6 (4.5–10.6) 11.4 (7.7–15.0) 46 9.3
No response 9.7 (6.3–13.0) 5.0 (2.5–7.5) 38 7.7
Total 1.5 (0.1–2.8) 7.8 (4.7–10.8) 21 4.2
CI: confidence interval; a Calculated based on the total number of answers given by the HCWs (n = 396); b Calculated based on the total number of an-
swers given by the HCWs (n = 659); c Calculated based on the total number of answers given by the HCWs (n = 496).
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the participants responded without having first been 
informed about the topics of interest. However, the re-
sults from the present analysis did show that the HCWs’ 
knowledge was often partial and incorrect.
Overall, it must be noted that all of the HCWs were still 
convinced that vaccinations are important instruments 
for infectious disease prevention, and they were aware 
of the key role that they play in promoting 4CmenB vac-
Tab. VI. Knowledge about the meningococcal meningitis epidemiology and meningococcal serogroup B multicomponent (4CMenB) vaccine.
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
HCWs’ k nowledge about the most common meningococcal serogroup in Italy
Sex (Male vs. Female*) 0.76 (0.4-1.2) 0.284 n.v.
Age (< 50 vs. ≥ 50*) 1.74 (1.0-2.9) 0.037 2.02 (1.1-3.6) 0.022
Children (No vs. Yes*) 1.28 (0.6-2.7) 0.513 n.v.
Degree (No vs. Yes*) 1.90 (1.1-3.1) 0.010 1.68 (0.4-6.3) 0.440
Profession (Doctor vs. Nurse*) 0.58 (0.3-0.9) 0.023 1.62 (0.4-6.0) 0.474
Department (Public health vs. Maternal childhood*) 0.17 (0.1-0.2) 0.000 0.29 (0.1-0.5) 0.000
Activity (Surveillance and control vs. Vaccination program*) 0.18 (0.0-0.3) 0.000 0.35 (0.1-0.8) 0.015
HCWs’ k nowledge about the meningococcal meningitis mortality rate
Sex (Male vs. Female*) 0.47 (0.2-0.8) 0.005 0.51 (0.2-0.9) 0.034
Age (< 50 vs.≥ 50*) 1.54 (0.9-2.6) 0.108 1.15 (0.6-2.0) 0.645
Children (No vs. Yes*) 1.09 (0.5-2.3) 0.811 n.v.
Degree (No vs. Yes*) 1.43 (0.8-2.3) 0.145 1.28 (0.3-4.5) 0.704
Profession (Doctor vs. Nurse*) 0.71 (0.4-1.1) 0.149 1.59 (0.4-5.8) 0.481
Department (Public health vs. Maternal childhood*) 0.54 (0.3-0.8) 0.013 0.80 (0.4-1.4) 0.464
Activity (Surveillance and control vs. Vaccination program*) 0.36 (0.1-0.7) 0.005 0.34 (0.1-0.8) 0.014
HCWs’ k nowledge about the 4CMenB vaccination schedule 
Sex (Male vs. Female*) 0.98 (0.5-1.7) 0.932 n.v.
Age (< 50 vs.≥ 50*) 0.77 (0.4-1.4) 0.389 n.v.
Children (No vs. Yes*) 0.69 (0.3-1.5) 0.358 n.v.
Degree (No vs. Yes*) 1.53 (0.8-2.6) 0.133 0.90 (0.1-4.6) 0.901
Profession (Doctor vs. Nurse*) 0.60 (0.3-1.0) 0.066 0.32 (0.0-1.6) 0.174
Department (Public health vs. Maternal childhood*) 2.95 (1.6-5.2) 0.000 3.31 (1.6-6.7) 0.001
Activity (Surveillance and control vs. Vaccination program*) 2.04 (0.9-4.6) 0.087 1.40 (0.5-3.6) 0.487
HCWs’ k nowledge about the 4CMenB vaccination being included among those recommended by the National Vaccine 
Prevention Plan
Sex (Male vs. Female*) 1.78 (1.0-2.9) 0.026 1.52 (0.8-2.6) 0.138
Age (< 50 vs.≥ 50*) 0.99 (0.5-1.6) 0.983 n.v.
Children (No vs. Yes*) 0.51 (0.2-1.1) 0.118 0.46 (0.1-1.1) 0.086
Degree (No vs. Yes*) 1.18 (0.7-1.9) 0.515 n.v.
Profession (Doctor vs. Nurse*) 0.88 (0.5-1.4) 0.590 n.v.
Department (Public health vs. Maternal childhood*) 3.04 (1.8-5.0) 0.000 3.22 (1.8-5.5) 0.000
Activity (Surveillance and control vs. Vaccination program*) 1.07 (0.5-2.0) 0.842 n.v.
HCWs’ k nowledge about the 4CMenB vaccination not being included among those implemented by the Regional Vaccine 
Prevention Plan in Campania
Sex (Male vs. Female*) 0.81 (0.4-1.3) 0.446 n.v.
Age (< 50 vs.≥ 50*) 0.93 (0.5-1.6) 0.811 n.v.
Children (No vs. Yes*) 1.42 (0.6-3.3) 0.413 n.v.
Degree (No vs. Yes*) 0.85 (0.5-1.4) 0.536 n.v.
Profession (Doctor vs. Nurse*) 1.34 (0.8-2.2) 0.257 n.v.
Department (Public health vs. Maternal childhood*) 0.50 (0.3-0.8) 0.010 0.36 (0.2-0.6) 0.001
Activity (Surveillance and control vs. Vaccination program*) 1.56 (0.7-3.2) 0.238 2.83 (1.2-6.3) 0.012
HCWs’ k nowledge about the increased risk  for adverse reactions when the 4CMenB vaccine is co-administered with another vaccine
Sex (Male vs. Female*) 1.02 (0.6-1.7) 0.931 n.v.
Age (< 50 vs.≥ 50*) 0.97 (0.5-1.6) 0.919 n.v.
Children (No vs. Yes*) 0.44 (0.2-0.9) 0.030 0.41 (0.1-0.8) 0.020
Degree (No vs. Yes*) 1.03 (0.6-1.7) 0.923 n.v.
Profession (Doctor vs. Nurse*) 0.85 (0.5-1.4) 0.521 n.v.
Department (Public health vs. Maternal childhood*) 1.78 (1.0-2.9) 0.025 1.76 (1.0-2.9) 0.037
Activity (Surveillance and control vs. Vaccination program*) 1.38 (0.6-2.7) 0.368 n.v.
OR: odds ratio; CI: confidence interval; HCWs: healthcare workers; n.v.: not valuated (p > 0.250 in the univariate analysis); * Reference category
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cinations, as well as other vaccines, and their need to be 
better informed.
Conclusions
This study highlights the importance of and need to im-
plement professional training courses for HCWs with 
interactive teaching methods. These should be suitable 
for an audience of experienced HCWs, as focus group, 
specific to the epidemiological aspects of meningococ-
cal disease and the 4CmenB vaccine. These interven-
tions would be useful for ensuring that HCWs are able 
to correctly answer patients’ questions about the vaccine 
risks and benefits, because they represent the interface 
between public institutions and citizens [23].
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